| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Entecavir | Ent-Entecavir | VE0010521 | View CAS 188399-46-4 |
| Entecavir | Entecavir 3-Epimer Hydrochloride | VE0010522 | View |
| Entecavir | Entecavir EP Impurity A | VE008161 | View |
| Entecavir | Entecavir EP Impurity D | VE009405 | View CAS 1367369-80-9 |
| Entecavir | Entecavir EP Impurity F | VE0011220 | View CAS 649761-24-0 |
| Entecavir | Entecavir-4-Epimer | VE0010523 | View |
| Entecavir | 4-Dimethylsilyl Entecavir | VE0010524 | View CAS 870614-82-7 |
| Catalogue No. | VE009405 |
| CAS No. | 1367369-80-9 |
| Molecular Formula | C12H15N5O3 |
| Molecular Weight | 277.28 g/mol |
| Parent drug | Entecavir |
| IUPAC Name | 2-Amino-9-[(1S, 3R, 4R)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1, 9-dihydro-6H-purin-6-one |
| Synonyms | 4’-epi-Entecavir |
| References | Dimou, Evangelini, et al. “The Role of Entecavir in the Treatment of Chronic Hepatitis B.” Therapeutics and Clinical Risk Management, vol. 3, no. 6, Dove Medical Press, 2007, pp. 1077–86, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2387288/. |
| Status | In-stock |
| ListName | Entecavir EP Impurity D |
| Exclusively Supplied by Veeprho | Exclusively Supplied by Veeprho |
"*" indicates required fields
